Nurix Therapeutics, Inc.
For the period ended Nov 30, 2025. Filed Jan 28, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jan 28, 2026
NRIX$15.88-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Item 15. Exhibits, Financial Statement Schedules
The following documents are filed as part of this Annual Report on Form 10-K:
(1)Financial Statements
The financial statements filed as part of this Annual Report on Form 10-K are listed in the “Index to Financial Statements” under Part II, Item 8 of this Annual Report on Form 10-K.
(2)Financial Statement Schedules
Financial statement schedules have been omitted in this Annual Report on Form 10-K because they are not applicable, not required under the instructions, or the information requested is set forth in the financial statements or related notes thereto.
(3)Exhibits
The following is a list of exhibits filed with this Annual Report on Form 10-K incorporated herein by reference (numbered in accordance with Item 601 of Regulation S-K):
EXHIBIT INDEX
| Incorporated by Reference · Filed or Furnished Herewith | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
| 3.1 | Restated Certificate of Incorporation | 10-Q | 001-39398 | 3.1 | October 14, 2020 |
| 3.2 | Amended and Restated Bylaws | 8-K | 001-39398 | 3.1 | December 16, 2022 |
| 4.1 | Form of Common Stock Certificate | S-1 | 333-239651 | 4.1 | July 2, 2020 |
| 4.2 | Description of Registrant’s Securities | 10-K | 001-39398 | 4.3 | February 9, 2023 |
| 4.3 | Form of Pre-funded Warrant | 8-K | 001-39398 | 4.1 | July 8, 2022 |
| 4.4 | Form of Pre-funded Warrant | 8-K | 001-39398 | 4.1 | April 12, 2024 |
| 10.1 | Form of Indemnity Agreement | S-1 | 333-239651 | 10.1 | July 2, 2020 |
| 10.2* | 2012 Equity Incentive Plan, as amended, and forms of award agreements | S-1 | 333-239651 | 10.2 | July 2, 2020 |
| 10.3* | 2020 Equity Incentive Plan and forms of award agreements | S-1/A | 333-239651 | 10.3 | July 20, 2020 |
| 10.4* | 2020 Employee Stock Purchase Plan and forms of award agreements | S-1/A | 333-239651 | 10.4 | July 20, 2020 |
| 10.5 | 2024 Equity Inducement Plan and forms of award agreements | S-8 | 333-282917 | 99.1 | October 31, 2024 |
| 10.6* | Employment Agreement, dated July 15, 2020, by and between the Registrant and Arthur T. Sands | S-1/A | 333-239651 | 10.5 | July 20, 2020 |
| 10.7* | Letter Agreement, dated June 15, 2020, by and between the Registrant and Arthur T. Sands | S-1 | 333-239651 | 10.11 | July 2, 2020 |
| 10.8* | Employment Agreement, dated July 15, 2020, by and between the Registrant and Gwenn Hansen | S-1/A | 333-239651 | 10.7 | July 20, 2020 |
| 10.9* | Employment Agreement, dated July 15, 2020, by and between the Registrant and Christine Ring | 10-K | 001-39398 | 10.7 | February 16, 2021 |
| 10.10* | Employment Agreement, dated July 15, 2020, by and between the Registrant and Hans van Houte | 10-K | 001-39398 | 10.9 | January 28, 2022 |
| 10.11* | Executive Severance and Change in Control Plan, as amended and restated on January 19, 2022, and form of Participation Agreement thereunder | 10-K | 001-39398 | 10.11 | January 28, 2022 |
| 10.12 | Lease Agreement, dated as of March 1, 2022, between 8800 Technology Forest Pl, LLC and the Registrant | 10-Q | 001-39398 | 10.1 | April 8, 2022 |
| 10.13 | First Amendment to Lease Agreement, dated August 25, 2023, by and between 8800 Technology Forest PL, LLC and the Registrant | 10-Q | 001-39398 | 10.2 | October 12, 2023 |
| 10.14†‡ | Sublease Agreement, dated as of February 21, 2025, between Janssen Research & Development, LLC and the Registrant | 10-Q | 001-39398 | 10.1 | April 8, 2025 |
| 10.15†‡ | Amendment No. 1 to Sublease Agreement, dated as of May 31, 2025, between Janssen Research & Development, LLC and the Registrant | 10-Q | 001-39398 | 10.1 | July 9, 2025 |
| 10.16†‡ | Collaboration, Option and License Agreement, dated June 10, 2019, by and between the Registrant and Gilead Sciences, Inc., as amended | S-1 | 333-239651 | 10.9 | July 2, 2020 |
| 10.17 | First Amendment to Collaboration, Option and License Agreement, dated August 13, 2019, by and between the Registrant and Gilead Sciences, Inc. | 10-Q | 001-39398 | 10.2 | October 6, 2022 |
| 10.18‡ | Second Amendment to Collaboration, Option and License Agreement, dated September 9, 2022, by and between the Registrant and Gilead Sciences, Inc. | 10-Q | 001-39398 | 10.3 | October 6, 2022 |
| 10.19†‡ | Collaboration and License Agreement, dated December 19, 2019, by and between the Registrant and Genzyme Corporation | S-1 | 333-239651 | 10.10 | July 2, 2020 |
| 10.20† | First Amendment to Collaboration and License Agreement, dated January 6, 2021, by and between the Registrant and Genzyme Corporation | 10-K | 001-39398 | 10.11 | February 16, 2021 |
| 10.21† | Second Amendment to Collaboration and License Agreement, dated December 16, 2021, by and between the Registrant and Genzyme Corporation | 10-Q | 001-39398 | 10.4 | October 6, 2022 |
| 10.22† | Third Amendment to Collaboration and License Agreement, dated July 7, 2022, by and between the Registrant and Genzyme Corporation | 10-Q | 001-39398 | 10.5 | October 6, 2022 |
| 10.23†‡ | Fourth Amendment to Collaboration and License Agreement, dated August 11, 2022, by and between the Registrant and Genzyme Corporation | 10-Q | 001-39398 | 10.6 | October 6, 2022 |
| 10.24†‡ | Fifth Amendment to Collaboration and License Agreement, dated November 3, 2023, by and between the Registrant and Genzyme Corporation | 10-K | 001-39398 | 10.24 | February 15, 2024 |
| 10.25† | Sixth Amendment to Collaboration and License Agreement, dated March 6, 2024, by and between the Registrant and Genzyme Corporation | 10-Q | 001-39398 | 10.1 | April 10, 2024 |
| 10.26†‡ | Collaboration and License Agreement, dated September 6, 2023, by and between the Registrant and Seagen Inc. | 10-K | 001-39398 | 10.25 | February 15, 2024 |
| 10.27 | Equity Distribution Agreement, dated August 4, 2021, by and between the Registrant and Piper Sandler & Co. | S-3 | 333-258448 | 1.2 | August 4, 2021 | |
| 10.28 | Amendment No. 1 to the Equity Distribution Agreement, dated July 11, 2024, by and between the Registrant and Piper Sandler & Co. | 8-K | 001-39398 | 10.1 | July 11, 2024 | |
| 10.29 | Amendment No. 2 to the Equity Distribution Agreement, dated October 31, 2024, by and between the Registrant and Piper Sandler & Co. | 8-K | 001-39398 | 10.1 | October 31, 2024 | |
| 19.1 | Insider Trading Policy | 10-K | 001-39398 | 19.1 | January 28, 2025 | |
| 21.1 | Subsidiaries of the Registrant | 10-K | 001-39398 | 21.1 | January 28, 2022 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm | X | ||||
| 24.1 | Power of Attorney (reference is made to the signature page hereto) | X | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 31.2 | Certification of Principal Financial and Accounting Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 32.1§ | Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 97.1 | Compensation Recovery Policy | 10-K | 001-39398 | 97.1 | February 15, 2024 | |
| 101.INS | Inline XBRL Instance Document - the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101) | X |
| * | Indicates a management or compensatory plan or arrangement in which directors or executive officers are eligible to participate. | |
| † | Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation S-K. | |
| ‡ | Registrant has omitted certain schedules pursuant to Item 601(a)(5) of Regulation S-K. | |
| § | The certifications furnished in Exhibits 32.1 hereto are deemed to accompany this Annual Report on Form 10-K and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.